About
Why Attend the Oligonucleotide-based Therapeutics Summit?
The Oligonucleotide-based Therapeutics Summit is the only industry-focused meeting solely dedicated to advancing oligonucleotides from discovery through late-stage development.
Driven by accelerating clinical progress and breakthroughs in chemical design and targeted delivery, oligonucleotides are redefining what’s possible, rapidly advancing as a leading therapeutic class for both proven and once “undruggable” targets.
Join 60+ biotech and pharma experts from Secarna, Genentech, Avidity Bioscience, Dyne Therapeutics, Biogen, Novo Nordisk, Stoke Therapeutics, and more to explore how the latest breakthroughs in chemistry and delivery are enabling safer, more targeted, and more effective therapies.
As the momentum accelerates, this is your opportunity to position yourself at the forefront of the oligonucleotide revolution, connect with scientific leaders shaping the field, and gain the insights you need to drive your programs forward.
Unmissable Event Highlights:
The Silver Lining of Setbacks, Reflecting on Clinical Trial Failures to shape Future Success for Oligonucleotide Therapeutics
Hear from experts on how trial challenges are shaping next-generation therapies with stronger efficacy and precision.
Hagen Cramer, Chief Technology Officer, QurAlis
Marcin Kortylewski, Professor, City of Hope
Unveiling the FORCE Platform, Advancing Oligonucleotide Delivery to Muscle Tissues
Dyne Therapeutics’ Tama Evron, Director of Platform Discovery, shares how the FORCE platform is revolutionizing muscle-targeted delivery, its unique modular properties, and the translation of preclinical insights into clinical proof-of-concept with DYNE-101.
Tama Evron, Director, Platform Discovery, Dyne Therapeutics
Optimizing Oligonucleotide Half-Life to Enhance Efficacy and Reduce CNS Toxicity
Join Meena as she explores how chemical modifications, structural engineering, and conjugation strategies can extend oligonucleotide half-life, optimize dosing regimens, and improve therapeutic windows while minimizing CNS toxicity.
Meena Indrakanti, Senior Vice President, Translational DMPK & Clinical Pharmacology, Stoke Therapeutics
-
- 60+ Attendees
-
- 16+ World-class Speakers
-
- Unrivalled networking opportunities
- Insights spanning multiple therapeutic areas
Attending Companies Include:
